An observational study in Thrombotic Thrombocytopenic Purpura, Atypical Hemolytic Uremic Syndrome and Pre-Eclampsia, sponsored by University College, London. Status unknown at 1 site in United Kingdom. Open to female participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2018-09-25.
Sponsored by University College, London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Purpura, Thrombotic Thrombocytopenic with a site in United Kingdom — none open to participants now, 1 under way, 1 of them phase 3. Purpura, Thrombotic Thrombocytopenic · United Kingdom.
Among the 17 studies in Purpura, Thrombotic Thrombocytopenic with a site in United Kingdom, this one is one of 2 that started in 2018, is one of 4 observational ones, and was the 10th registered.
67 studies on the registry are indexed under Purpura, Thrombotic Thrombocytopenic; 18 are open to participants now.
Browse Purpura, Thrombotic Thrombocytopenic studies →None of the 17 studies in Purpura, Thrombotic Thrombocytopenic with a site in United Kingdom is open now. The open studies under Purpura, Thrombotic Thrombocytopenic, anywhere →
Of the 16 Purpura, Thrombotic Thrombocytopenic studies recruiting now, 12 (75%) set no upper age limit and 1 (6%) stops at 75 or younger; 9 take children under 18; 1 takes healthy volunteers.
This study: 16 Years and older · female.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 2 started in 2018.
This study's planned enrollment of 150 is close to the median of 156 across 27 observational studies indexed under Purpura, Thrombotic Thrombocytopenic.
Median enrollment 51 across the 13 interventional studies, 200 across the 4 observational. Of the 12 that completed or were terminated, 7 (58%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 17 have an industry lead sponsor. The 10 most frequent:
University College, London is the lead sponsor of 652 studies on the registry; 149 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.
University College, London has 3 studies filed under Purpura, Thrombotic Thrombocytopenic — fewer than ten, so there is no comparison to draw.
1 of the studies in Purpura, Thrombotic Thrombocytopenic with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04683003Phase 3TakedaA Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura | 2027-03-16 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Purpura, Thrombotic Thrombocytopenic with a site in United Kingdom, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
A single site observational study aiming to:
(i) Identify cases of previously undiagnosed thrombotic thrombocytopenic purpura (TTP) and atypical haemolytic syndrome (aHUS) in a cohort of women with complicated pregnancies (ii) Characterise the clinical features of these cases and (ii) Identify clinical features or biomarkers which may help distinguish TTP/aHUS from other complications of pregnancy such as preeclampsia
All women receiving obstetric care at University College Hospitals London NHS Trust over the study period
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ADAMTS 13, complement and angiogenic biomarkers
Frequency of TTP and aHUS in the cohort
Number of new cases identified as a percentage of sample size
Time frame: At study completion, approximately 18 months after recruitment of first patient
Started Sep 2018 (actual). Primary completion is estimated for Mar 2020, 17 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Purpura, Thrombotic Thrombocytopenic →